Spots Global Cancer Trial Database for A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
Official Title: A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS015 In Patients With Advanced Solid Tumors
Study ID: NCT05770310
Conditions
Interventions
Study Description
Brief Summary: This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of JS015 in patients with advanced solid tumors. The Recommended dose for phase II trial （RP2D） was determined based on the safety, pharmacokinetics, and initial efficacy data of the dose escalation and extension.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Cancer Hospital, Beijing, Beijing, China
Affiliated Cancer Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
Shandong Cancer Hospital, Jinan, Shandong, China
Shanghai Oriental Hospital, Shanghai, Shanghai, China
Contact Details
Name: Jin Li, Medical Doctor
Affiliation: Affiliation: Shanghai Oriental Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jinming Yu, Medical Doctor
Affiliation: Shandong Cancer Hospital and Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
